Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (11-20 of 202) with videos related to

Pageof 21
Sort By:
Clinical Chemistry|May 10, 2013
Companion biomarkers: paving the pathway to personalized treatment for cancerMichael J Duffy, John Crown
Critical Reviews in Clinical Laboratory Sciences|November 8, 2023
Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?Michael J Duffy, John Crown
Annals of Translational Medicine|October 22, 2014
Monitoring response to therapy in patients with cancer: is circulating DNA the answer?Michael J Duffy, John Crown
Clinical Chemistry|September 20, 2008
A personalized approach to cancer treatment: how biomarkers can helpMichael J Duffy, John Crown
Journal of the National Cancer Institute|June 5, 2003
Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxelJosephine Ballot, Deirdre McDonnell, John Crown
Acta Oncologica (Stockholm, Sweden)|October 16, 2013
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancerDavid Candon, Joan Healy, John Crown
Oncotargets and Therapy|December 4, 2010
Targeted treatment of advanced and metastaticbreast cancer with lapatinibBrendan Corkery, Norma O'Donovan, John Crown
Drug Discovery Today|June 28, 2011
Truncated HER2: implications for HER2-targeted therapeuticsRadoslaw Zagozdzon, William M Gallagher, John Crown
Investigational New Drugs|May 26, 2023
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cellsMinhong Tang, John Crown, Michael J Duffy
Cancer Treatment Reviews|August 6, 2010
Use of molecular markers for predicting therapy response in cancer patientsMichael J Duffy, Norma O'Donovan, John Crown
Pageof 21

Showing results (11-20 of 202) with videos related to

Sort By:
Pageof 21
Clinical Chemistry|May 10, 2013
Companion biomarkers: paving the pathway to personalized treatment for cancerMichael J Duffy, John Crown
Critical Reviews in Clinical Laboratory Sciences|November 8, 2023
Circulating tumor DNA (ctDNA): can it be used as a pan-cancer early detection test?Michael J Duffy, John Crown
Annals of Translational Medicine|October 22, 2014
Monitoring response to therapy in patients with cancer: is circulating DNA the answer?Michael J Duffy, John Crown
Clinical Chemistry|September 20, 2008
A personalized approach to cancer treatment: how biomarkers can helpMichael J Duffy, John Crown
Journal of the National Cancer Institute|June 5, 2003
Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxelJosephine Ballot, Deirdre McDonnell, John Crown
Acta Oncologica (Stockholm, Sweden)|October 16, 2013
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancerDavid Candon, Joan Healy, John Crown
Oncotargets and Therapy|December 4, 2010
Targeted treatment of advanced and metastaticbreast cancer with lapatinibBrendan Corkery, Norma O'Donovan, John Crown
Drug Discovery Today|June 28, 2011
Truncated HER2: implications for HER2-targeted therapeuticsRadoslaw Zagozdzon, William M Gallagher, John Crown
Investigational New Drugs|May 26, 2023
Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cellsMinhong Tang, John Crown, Michael J Duffy
Cancer Treatment Reviews|August 6, 2010
Use of molecular markers for predicting therapy response in cancer patientsMichael J Duffy, Norma O'Donovan, John Crown
Pageof 21